JP2020502132A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502132A5 JP2020502132A5 JP2019531806A JP2019531806A JP2020502132A5 JP 2020502132 A5 JP2020502132 A5 JP 2020502132A5 JP 2019531806 A JP2019531806 A JP 2019531806A JP 2019531806 A JP2019531806 A JP 2019531806A JP 2020502132 A5 JP2020502132 A5 JP 2020502132A5
- Authority
- JP
- Japan
- Prior art keywords
- skin
- composition according
- plasminogen
- drug composition
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940079593 drug Drugs 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 102000013566 Plasminogen Human genes 0.000 claims 7
- 108010051456 Plasminogen Proteins 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010050207 Skin fibrosis Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 108010087750 lysyl-plasminogen Proteins 0.000 claims 1
- 108010049112 miniplasminogen Proteins 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000037380 skin damage Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 206010040882 skin lesion Diseases 0.000 claims 1
- 231100000444 skin lesion Toxicity 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/110174 | 2016-12-15 | ||
| CN2016110174 | 2016-12-15 | ||
| PCT/CN2017/089054 WO2018107694A1 (zh) | 2016-12-15 | 2017-06-19 | 一种预防和治疗皮肤纤维化的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020502132A JP2020502132A (ja) | 2020-01-23 |
| JP2020502132A5 true JP2020502132A5 (cg-RX-API-DMAC10.html) | 2020-07-30 |
Family
ID=62557850
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531805A Active JP7213552B2 (ja) | 2016-12-15 | 2017-06-19 | 肝の繊維化を予防及び治療するための方法 |
| JP2019531808A Active JP7213553B2 (ja) | 2016-12-15 | 2017-06-19 | 肺の繊維化を予防及び治療するための方法 |
| JP2019531811A Active JP7313058B2 (ja) | 2016-12-15 | 2017-06-19 | 組織器官の繊維化を予防及び治療するための方法 |
| JP2019531806A Pending JP2020502132A (ja) | 2016-12-15 | 2017-06-19 | 皮膚の繊維化を予防及び治療するための方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531805A Active JP7213552B2 (ja) | 2016-12-15 | 2017-06-19 | 肝の繊維化を予防及び治療するための方法 |
| JP2019531808A Active JP7213553B2 (ja) | 2016-12-15 | 2017-06-19 | 肺の繊維化を予防及び治療するための方法 |
| JP2019531811A Active JP7313058B2 (ja) | 2016-12-15 | 2017-06-19 | 組織器官の繊維化を予防及び治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20190314466A1 (cg-RX-API-DMAC10.html) |
| EP (4) | EP3556380A4 (cg-RX-API-DMAC10.html) |
| JP (4) | JP7213552B2 (cg-RX-API-DMAC10.html) |
| CN (4) | CN110121358A (cg-RX-API-DMAC10.html) |
| CA (3) | CA3046669A1 (cg-RX-API-DMAC10.html) |
| TW (6) | TWI670075B (cg-RX-API-DMAC10.html) |
| WO (5) | WO2018107694A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7213552B2 (ja) | 2016-12-15 | 2023-01-27 | タレンゲン インターナショナル リミテッド | 肝の繊維化を予防及び治療するための方法 |
| CA3067890A1 (en) | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
| TWI868051B (zh) * | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| EP4094776A4 (en) * | 2020-02-11 | 2023-05-17 | Talengen International Limited | METHODS AND MEDICATIONS FOR THE TREATMENT OF VIRAL PENMONIA |
| CN115885049A (zh) * | 2020-08-20 | 2023-03-31 | 泰伦基国际有限公司 | 一种治疗肿瘤的方法和药物 |
| CN114984032B (zh) * | 2022-06-27 | 2023-07-07 | 四川大学 | Dna四面体框架核酸-绿原酸复合物及其在制备治疗肝纤维化的药物中的用途 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4645668A (en) * | 1983-08-04 | 1987-02-24 | Biospecifics, Nv | Method for the prevention and treatment of scars with enzymes |
| GB8721951D0 (en) | 1987-09-18 | 1987-10-28 | Thrombosis Research Trust | Organic compounds |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| JP4426650B2 (ja) | 1996-05-03 | 2010-03-03 | アボット・ラボラトリーズ | 新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法 |
| EP1001985A1 (en) | 1997-06-26 | 2000-05-24 | Karolinska Innovations AB | Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| US6365364B1 (en) | 1998-08-20 | 2002-04-02 | University Of Vermont And State Agriculture College | Angiogenesis inhibitors and uses thereof |
| US7763580B2 (en) | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| WO2002040510A2 (en) | 2000-11-02 | 2002-05-23 | Bristol-Myers Squibb Company | Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors |
| MXPA00011713A (es) | 2000-11-28 | 2002-05-31 | Tgt Lab S A De C V | Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe |
| US7067492B2 (en) | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| US20050124036A1 (en) * | 2002-02-06 | 2005-06-09 | Rudy Susilo | Method for producing recombinant proteins in micro-organisms |
| MXPA04007585A (es) * | 2002-02-06 | 2005-09-20 | N Zyme Biotec Gmbh | Metodo para la produccion de proteinas recombinantes en microorganismos. |
| JP2006507297A (ja) | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
| EP1569899B1 (en) | 2002-12-10 | 2006-06-28 | Wyeth | Substituted 3-alkyl- and 3-arylalkyl-1h-indol-1-yl-acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| US20050250694A1 (en) | 2003-10-10 | 2005-11-10 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
| WO2006023864A1 (en) | 2004-08-23 | 2006-03-02 | Wyeth | Pyrrolo-naphthyl acids as pai-1 inhibitors |
| CA2662101C (en) | 2006-08-28 | 2015-07-07 | Omnio Healer Ab | Candidates against infection |
| US20100080773A1 (en) | 2008-09-26 | 2010-04-01 | Sdg, Inc. | Orally Bioavailable Lipid-Based Constructs |
| US8101394B2 (en) | 2007-11-29 | 2012-01-24 | Grifols Therapeutics Inc. | Recombinantly modified plasmin |
| WO2009111625A2 (en) * | 2008-03-05 | 2009-09-11 | Board Of Regents, The University Of Texas System | Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis |
| NZ597452A (en) * | 2009-07-10 | 2013-10-25 | Thrombogenics Nv | Variants of plasminogen and plasmin |
| CN101628113B (zh) * | 2009-08-18 | 2012-01-04 | 南京农业大学 | 蚯蚓纤溶酶抗肝纤维化的应用 |
| EA201290195A1 (ru) | 2009-11-07 | 2012-12-28 | Астьют Медикал, Инк. | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности |
| US20120114652A1 (en) * | 2010-05-03 | 2012-05-10 | Abbott Laboratories | Anti-pai-1 antibodies and methods of use thereof |
| CN102121023B (zh) | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| CA2823491A1 (en) * | 2011-01-05 | 2012-07-12 | Thrombogenics Nv | Plasminogen and plasmin variants |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| US9655973B2 (en) | 2012-03-09 | 2017-05-23 | Vascular Biosciences | Orally active, cell-penetrating homing peptide and methods of using same |
| KR101467109B1 (ko) | 2013-07-10 | 2014-12-01 | 영남대학교 산학협력단 | Ｂｉｘ02189 화합물을 유효성분으로 포함하는 폐섬유증 예방 또는 치료용 조성물 |
| BR112016002753A2 (pt) * | 2013-08-13 | 2017-11-21 | Sanofi Sa | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| TW201722994A (zh) | 2013-08-13 | 2017-07-01 | 賽諾菲公司 | 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途 |
| US20160199466A1 (en) | 2013-08-20 | 2016-07-14 | Trustees Of Dartmouth College | Methods For Treating Tissue Fibrosis |
| MX2016010852A (es) | 2014-02-21 | 2016-10-26 | Astellas Pharma Inc | Anticuerpo anti-inhibidor de activador de plasminogeno 1 (pai-1) humano novedoso. |
| PY1577621A (es) | 2014-12-19 | 2017-10-02 | Prometic Biotherapeutics Inc | Composicion farmaceutica que comprende plasminogeno y uso para el mismo |
| TWI801331B (zh) | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| CA3008466C (en) | 2015-12-18 | 2023-06-20 | Talengen International Limited | Method for preventing or treating radiation and chemical damage |
| CN106890324A (zh) | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗糖尿病肾病的方法 |
| CN106890318A (zh) | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗糖尿病性心脏病的新方法 |
| WO2017101866A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种用于预防或治疗急性及慢性血栓的方法 |
| TWI653981B (zh) | 2015-12-18 | 2019-03-21 | 深圳瑞健生命科學硏究院有限公司 | Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury |
| WO2017101871A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗心血管病的新方法 |
| CN106890320A (zh) | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种用于预防或治疗急性及慢性血栓的方法 |
| JP7213552B2 (ja) | 2016-12-15 | 2023-01-27 | タレンゲン インターナショナル リミテッド | 肝の繊維化を予防及び治療するための方法 |
| WO2018107701A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种新的降血糖和提高糖耐量的药物 |
| TWI677348B (zh) * | 2016-12-15 | 2019-11-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種改善心臟病變的方法 |
| TWI750189B (zh) * | 2016-12-15 | 2021-12-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療冠狀動脈粥樣硬化及其併發症的方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| CA3047170A1 (en) * | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method for preventing and treating drug-induced renal injury |
| CA3067890A1 (en) * | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
-
2017
- 2017-06-19 JP JP2019531805A patent/JP7213552B2/ja active Active
- 2017-06-19 US US16/470,162 patent/US20190314466A1/en not_active Abandoned
- 2017-06-19 EP EP17880059.5A patent/EP3556380A4/en active Pending
- 2017-06-19 US US16/470,179 patent/US11154595B2/en active Active
- 2017-06-19 WO PCT/CN2017/089054 patent/WO2018107694A1/zh not_active Ceased
- 2017-06-19 CA CA3046669A patent/CA3046669A1/en not_active Abandoned
- 2017-06-19 CA CA3046671A patent/CA3046671C/en active Active
- 2017-06-19 US US16/470,172 patent/US11219669B2/en active Active
- 2017-06-19 CN CN201780078132.8A patent/CN110121358A/zh active Pending
- 2017-06-19 EP EP17880398.7A patent/EP3556382A4/en active Pending
- 2017-06-19 JP JP2019531808A patent/JP7213553B2/ja active Active
- 2017-06-19 TW TW106120456A patent/TWI670075B/zh active
- 2017-06-19 WO PCT/CN2017/089057 patent/WO2018107697A1/zh not_active Ceased
- 2017-06-19 JP JP2019531811A patent/JP7313058B2/ja active Active
- 2017-06-19 CN CN201780078123.9A patent/CN110114080A/zh active Pending
- 2017-06-19 WO PCT/CN2017/089058 patent/WO2018107698A1/zh not_active Ceased
- 2017-06-19 CN CN201780078169.0A patent/CN110191718A/zh active Pending
- 2017-06-19 WO PCT/CN2017/089053 patent/WO2018107693A1/zh not_active Ceased
- 2017-06-19 WO PCT/CN2017/089056 patent/WO2018107696A1/zh not_active Ceased
- 2017-06-19 CN CN201780078166.7A patent/CN110139668A/zh active Pending
- 2017-06-19 CA CA3047174A patent/CA3047174A1/en not_active Abandoned
- 2017-06-19 TW TW106120454A patent/TWI752044B/zh active
- 2017-06-19 EP EP17881523.9A patent/EP3556389A4/en active Pending
- 2017-06-19 TW TW106120457A patent/TW201822790A/zh unknown
- 2017-06-19 TW TW106120449A patent/TWI657823B/zh active
- 2017-06-19 JP JP2019531806A patent/JP2020502132A/ja active Pending
- 2017-06-19 EP EP17882248.2A patent/EP3556395A4/en active Pending
- 2017-06-19 US US16/470,186 patent/US11071772B2/en active Active
- 2017-06-19 TW TW106120453A patent/TWI734798B/zh active
- 2017-06-19 TW TW110101502A patent/TW202123955A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019002960A1 (es) | Péptido con actividad anti-obesidad y anti-diabetes y uso del mismo. (divisional solicitud 201702718) | |
| Laureano et al. | Facial bacterial infections: folliculitis | |
| BR112021006167A8 (pt) | Partículas de rna compreendendo polisarcosina | |
| JP2016516808A5 (cg-RX-API-DMAC10.html) | ||
| JP2014505733A5 (cg-RX-API-DMAC10.html) | ||
| BR112014019431A8 (pt) | Método compartimentalizado de distribuição de ácido nucleico e composições e usos desses | |
| BR112012018500A2 (pt) | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas | |
| JP2017518370A5 (cg-RX-API-DMAC10.html) | ||
| Gilbert et al. | Efficacy of botulinum neurotoxin type A for treating recalcitrant plaque psoriasis | |
| JP2017537936A5 (cg-RX-API-DMAC10.html) | ||
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| JP2020524689A5 (cg-RX-API-DMAC10.html) | ||
| Kim et al. | Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial | |
| AR049518A1 (es) | Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados | |
| SA519410993B1 (ar) | النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية | |
| Sadeghian et al. | Treatment of localized psoriasis with a topical formulation of zinc pyrithione | |
| Kim et al. | Tetracyclines revisited: tetracyclines in the field of dermatology | |
| CL2020001791A1 (es) | Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas. | |
| Neri et al. | Botulinum toxin A as an alternative treatment for folliculitis decalvans | |
| JP2013520447A5 (cg-RX-API-DMAC10.html) | ||
| DK2004235T3 (da) | Sammensætning til kosmetisk eller farmaceutisk-dermatologisk anvendelse | |
| Kim et al. | Macrophages in the pathogenesis of monogenic muscular dystrophies: inflammation, fibrosis, and therapeutic implications | |
| AR108793A1 (es) | Composiciones que comprenden timolol y un agente antiinflamatorio | |
| Saco et al. | Severe radiation dermatitis associated with concomitant vemurafenib therapy in a patient with metastatic melanoma |